What is IsomAb?
IsomAb is a biotechnology firm focused on a distinct strategy for identifying, evaluating, and developing isoform-specific antibodies to address diseases with limited or no current treatment options. Leveraging a combined bioinformatics and knowledge-based platform, the company has identified ISM-001. This candidate specifically targets the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A). The development is built upon two decades of foundational research by IsomAb's founders, with evidence suggesting that reducing serum levels of VEGF-A165b is critical for promoting new blood vessel formation in patients suffering from ischemic diseases.
How much funding has IsomAb raised?
IsomAb has raised a total of $9.5M across 1 funding round:
Other Financing Round
$9.5M
Other Financing Round (2024): $9.5M with participation from Broadview Ventures
Key Investors in IsomAb
Broadview Ventures
Broadview Ventures is a venture capital firm with a dedicated focus on impact investing within the cardiovascular disease and stroke sectors. They aim to accelerate the development of innovative diagnostic and therapeutic technologies, actively investing in promising treatments to benefit patients. Their portfolio is diversified across various cardiovascular health technologies.
What's next for IsomAb?
The recent major enterprise-level funding positions IsomAb for significant advancement in its preclinical and clinical development pipelines. This capital infusion is expected to accelerate the validation of ISM-001 and potentially expand the company's research into other isoform-specific antibody targets. The strategic backing suggests confidence from investors in IsomAb's unique scientific approach and its potential to create impactful therapies for underserved patient populations.
See full IsomAb company page
